Brokerages Set Aura Biosciences, Inc. (NASDAQ:AURA) PT at $23.00

Shares of Aura Biosciences, Inc. (NASDAQ:AURA) have earned an average rating of “Buy” from the seven ratings firms that are presently covering the stock, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $23.00.

Several analysts have issued reports on the company. Cowen restated a “buy” rating on shares of Aura Biosciences in a research note on Friday, October 18th. Evercore ISI upgraded shares of Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 16th. Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a report on Monday, September 9th. JMP Securities increased their target price on Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a research note on Friday, September 13th. Finally, HC Wainwright restated a “buy” rating and issued a $22.00 price target on shares of Aura Biosciences in a research note on Thursday, November 14th.

Aura Biosciences Trading Down 0.4 %

Shares of AURA opened at $8.41 on Friday. The company’s fifty day simple moving average is $9.70 and its 200 day simple moving average is $8.73. Aura Biosciences has a 1-year low of $6.63 and a 1-year high of $12.38. The company has a market cap of $420.08 million, a price-to-earnings ratio of -4.86 and a beta of 0.26.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.02. As a group, research analysts forecast that Aura Biosciences will post -1.66 earnings per share for the current year.

Insider Activity at Aura Biosciences

In other Aura Biosciences news, CTO Mark Plavsic sold 7,383 shares of the business’s stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $9.85, for a total transaction of $72,722.55. Following the sale, the chief technology officer now directly owns 121,132 shares of the company’s stock, valued at $1,193,150.20. The trade was a 5.74 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Julie B. Feder sold 25,131 shares of the firm’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $12.03, for a total transaction of $302,325.93. Following the transaction, the chief financial officer now directly owns 134,276 shares of the company’s stock, valued at $1,615,340.28. The trade was a 15.77 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 79,081 shares of company stock valued at $891,353 in the last 90 days. 5.40% of the stock is owned by corporate insiders.

Institutional Trading of Aura Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of AURA. American Century Companies Inc. acquired a new position in shares of Aura Biosciences in the second quarter worth approximately $119,000. SG Americas Securities LLC acquired a new position in shares of Aura Biosciences in the 3rd quarter worth approximately $169,000. Rhumbline Advisers increased its position in shares of Aura Biosciences by 39.6% during the second quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock worth $480,000 after buying an additional 18,011 shares during the period. The Manufacturers Life Insurance Company raised its stake in Aura Biosciences by 14.6% during the second quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company’s stock worth $487,000 after buying an additional 8,194 shares during the last quarter. Finally, Barclays PLC lifted its holdings in Aura Biosciences by 256.5% in the third quarter. Barclays PLC now owns 61,010 shares of the company’s stock valued at $544,000 after buying an additional 43,897 shares during the period. 96.75% of the stock is currently owned by institutional investors and hedge funds.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.